Development of a sustained release dosage form for α-lipoic acid.: I.: design and in vitro evaluation

被引:20
作者
Bernkop-Schnürch, A
Schuhbauer, H
Clausen, AE
Hanel, R
机构
[1] Univ Innsbruck, Dept Pharmaceut Technol, Inst Pharm, A-6020 Innsbruck, Austria
[2] Univ Vienna, Ctr Pharm, Inst Pharmaceut Technol & Biopharmaceut, Vienna, Austria
[3] Degussa AG Trostberg, Trostberg, Germany
关键词
alpha-lipoic acid; chitosan; controlled drug release; oral drug delivery; permeation studies;
D O I
10.1081/DDC-120027508
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The purpose of this study was the design and evaluation of a sustained release dosage form for the oral administration of alpha-lipoic acid. The cationic polymer chitosan was used in order to provide a controlled drug release based on ionic interactions with the anionic drug. The effect of such ionic interactions on the release of alpha-lipoic acid could be verified by diffusion studies. In vitro release studies with tablets (diameter: 10.0 mm; thickness: similar to4 mm) containing 80% alpha-lipoic acid and 20% chitosan acetate showed a controlled drug release over a time period of 24 h. Raising the ratio of chitosan acetate in such delivery systems led to an even stronger retardation of drug release. In addition, permeation studies carried out in Ussing-type chambers with freshly excised intestinal mucosa from guinea pigs demonstrated no significant (p<0.05) influence of the degree of drug ionization on its absorption behavior. The apparent permeability coefficient (P-app) for alpha-lipoic acid was determined to be 1.39 +/- 0.28x10(-5) cm/sec at pH 6.4 (means +/- SD). The use of a sustained delivery system for alpha-lipoic acid, which is based on ionic interactions, should therefore have no influence on the absorption behavior of the drug. The sustained release dosage forms described here might provide a constant plasma level of the drug being highly beneficial for various therapeutic reasons.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 20 条
  • [1] Chitosan and its derivatives:: potential excipients for peroral peptide delivery systems
    Bernkop-Schnürch, A
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2000, 194 (01) : 1 - 13
  • [2] Clausen AE, 2000, J PHARM SCI-US, V89, P1253, DOI 10.1002/1520-6017(200010)89:10<1253::AID-JPS3>3.0.CO
  • [3] 2-8
  • [4] Improvement of insulin-stimulated glucose-disposal in type 2 diabetes after repeated parenteral administration of thioctic acid
    Jacob, S
    Henriksen, EJ
    Tritschler, HJ
    Augustin, HJ
    Dietze, GJ
    [J]. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1996, 104 (03) : 284 - 288
  • [5] The antioxidant alpha-lipoic acid enhances insulin-stimulated glucose metabolism in insulin-resistant rat skeletal muscle
    Jacob, S
    Streeper, RS
    Fogt, DL
    Hokama, JY
    Tritschler, HJ
    Dietze, GJ
    Henriksen, EJ
    [J]. DIABETES, 1996, 45 (08) : 1024 - 1029
  • [6] INVITRO EVALUATION OF MUCOADHESIVE PROPERTIES OF CHITOSAN AND SOME OTHER NATURAL POLYMERS
    LEHR, CM
    BOUWSTRA, JA
    SCHACHT, EH
    JUNGINGER, HE
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1992, 78 (01) : 43 - 48
  • [7] Degradation of partially N-acetylated chitosans with hen egg white and human lysozyme
    Nordtveit, RJ
    Varum, KM
    Smidsrod, O
    [J]. CARBOHYDRATE POLYMERS, 1996, 29 (02) : 163 - 167
  • [8] Palm K, 1999, J PHARMACOL EXP THER, V291, P435
  • [9] PETER G, 1995, ARZNEIMITTELFORSCH, V45-1, P293
  • [10] RUPPRECHT H, 1987, CONTROLLED DRUG DELI, V17, P197